{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:54:18Z","timestamp":1760576058503,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1997,1,1]],"date-time":"1997-01-01T00:00:00Z","timestamp":852076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1997,1,1]],"date-time":"1997-01-01T00:00:00Z","timestamp":852076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[1997]]},"DOI":"10.1016\/s0936-6555(97)80132-x","type":"journal-article","created":{"date-parts":[[2005,4,29]],"date-time":"2005-04-29T07:58:49Z","timestamp":1114761529000},"page":"385-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Chemotherapy for neuroendocrine tumours: The beatson oncology centre experience"],"prefix":"10.1016","volume":"9","author":[{"given":"M.Q.F.","family":"Hatton","sequence":"first","affiliation":[]},{"given":"N.S.","family":"Reed","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0936-6555(97)80132-X_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00000658-198708000-00001","article-title":"Malignant carcinoid tumours: an analysis of 103 patients with regard to tumour localisation, hormonal production and survvial","volume":"206","author":"Norhiem","year":"1987","journal-title":"Ann Surg"},{"key":"10.1016\/S0936-6555(97)80132-X_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinoma with combined etoposide and cisplatin","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/S0936-6555(97)80132-X_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant phaeochromocytoma: effective treatment with a combination of cylcophosphamide, vincristine and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0936-6555(97)80132-X_bib4","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/0959-8049(92)90173-Y","article-title":"Palliation of malignant phaeochromocytoma with combination chemotherapy","volume":"28","author":"Senen","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/S0936-6555(97)80132-X_bib5","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.1984.2.7.742","article-title":"Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26","volume":"2","author":"Shafford","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0936-6555(97)80132-X_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/oxfordjournals.annonc.a059049","article-title":"A Phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology Group","volume":"6","author":"Di Bartolomeo","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/S0936-6555(97)80132-X_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"74","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/S0936-6555(97)80132-X_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/S0936-6555(97)80132-X_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/02841869309083920","article-title":"Salvage treatment after r-interferon alpha 2A in advanced neuro-endocrine tumours","volume":"32","author":"Zilembo","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1016\/S0936-6555(97)80132-X_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","article-title":"Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors","volume":"77","author":"Di Bartolomeo","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/S0936-6555(97)80132-X_bib11","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/1097-0142(19931115)72:10<3099::AID-CNCR2820721035>3.0.CO;2-4","article-title":"Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon alpha 2a","volume":"72","author":"Bajetta","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/S0936-6555(97)80132-X_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K","article-title":"Treatment of advanced medullary thyroid carcinoma with a combination of cyclopho-sphamide, vincristine and dacarbazine","volume":"73","author":"Wu","year":"1994","journal-title":"Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093665559780132X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093665559780132X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:55:10Z","timestamp":1760543710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093665559780132X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1997]]}},"alternative-id":["S093665559780132X"],"URL":"https:\/\/doi.org\/10.1016\/s0936-6555(97)80132-x","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[1997]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy for neuroendocrine tumours: The beatson oncology centre experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0936-6555(97)80132-X","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1997 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}